Financial Ratios Fisher & Paykel Healthcare Corporation Limited
Equities
FPH
NZFAPE0001S2
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
38.03 NZD | -0.96% | +1.28% | +61.14% |
Fiscal Period: March | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 17.95 | 25.37 | 15.11 | 9.63 | 9.85 | |||||
Return on Total Capital | 22.45 | 32.34 | 18.45 | 11.27 | 11.48 | |||||
Return On Equity % | 30.45 | 42.02 | 23.55 | 14.58 | 7.55 | |||||
Return on Common Equity | 30.45 | 42.02 | 23.55 | 14.58 | 7.55 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 66.14 | 63.19 | 62.6 | 59.35 | 59.93 | |||||
SG&A Margin | 26.75 | 20.12 | 23.38 | 27.32 | 28.28 | |||||
EBITDA Margin % | 33.68 | 39.64 | 34.4 | 25.9 | 25.52 | |||||
EBITA Margin % | 30.66 | 36.75 | 34.29 | 22.17 | 21.5 | |||||
EBIT Margin % | 30.02 | 36.14 | 30.06 | 21.01 | 20.28 | |||||
Income From Continuing Operations Margin % | 22.73 | 26.59 | 22.41 | 15.83 | 7.61 | |||||
Net Income Margin % | 22.73 | 26.59 | 22.41 | 15.83 | 7.61 | |||||
Net Avail. For Common Margin % | 22.73 | 26.59 | 22.41 | 15.83 | 7.61 | |||||
Normalized Net Income Margin | 18.32 | 22.77 | 18.74 | 12.97 | 11.97 | |||||
Levered Free Cash Flow Margin | 11.58 | 17.26 | 4.65 | 1.7 | 2.62 | |||||
Unlevered Free Cash Flow Margin | 11.77 | 17.42 | 4.83 | 1.97 | 3.27 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.96 | 1.12 | 0.8 | 0.73 | 0.78 | |||||
Fixed Assets Turnover | 1.89 | 2.44 | 1.83 | 1.5 | 1.4 | |||||
Receivables Turnover (Average Receivables) | 7.68 | 10.25 | 10.06 | 9.81 | 8.73 | |||||
Inventory Turnover (Average Inventory) | 3.03 | 3.48 | 2 | 1.77 | 2.04 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.55 | 2.15 | 2.92 | 2.67 | 1.83 | |||||
Quick Ratio | 1.1 | 1.42 | 1.56 | 1.3 | 0.9 | |||||
Operating Cash Flow to Current Liabilities | 0.96 | 1.46 | 1.07 | 0.82 | 1.12 | |||||
Days Sales Outstanding (Average Receivables) | 47.63 | 35.61 | 36.3 | 37.21 | 41.91 | |||||
Days Outstanding Inventory (Average Inventory) | 120.86 | 104.91 | 182.64 | 205.78 | 179.8 | |||||
Average Days Payable Outstanding | 51.94 | 27.06 | 28.11 | 27.2 | 21.13 | |||||
Cash Conversion Cycle (Average Days) | 116.55 | 113.45 | 190.83 | 215.8 | 200.58 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 14.22 | 7.88 | 6.21 | 8.32 | 10.75 | |||||
Total Debt / Total Capital | 12.45 | 7.3 | 5.85 | 7.68 | 9.71 | |||||
LT Debt/Equity | 4.68 | 6.1 | 5.2 | 7.1 | 5.28 | |||||
Long-Term Debt / Total Capital | 4.1 | 5.65 | 4.89 | 6.56 | 4.77 | |||||
Total Liabilities / Total Assets | 32.14 | 26.7 | 20.28 | 20.46 | 22.9 | |||||
EBIT / Interest Expense | 97.26 | 142.46 | 103.18 | 49.58 | 19.42 | |||||
EBITDA / Interest Expense | 111.72 | 158.56 | 120.88 | 63.6 | 25.41 | |||||
(EBITDA - Capex) / Interest Expense | 74.46 | 126.52 | 92.63 | 35.57 | 8.01 | |||||
Total Debt / EBITDA | 0.32 | 0.15 | 0.18 | 0.34 | 0.41 | |||||
Net Debt / EBITDA | -0.01 | -0.33 | -0.31 | 0.06 | 0.23 | |||||
Total Debt / (EBITDA - Capex) | 0.48 | 0.19 | 0.23 | 0.61 | 1.3 | |||||
Net Debt / (EBITDA - Capex) |